INFO & CONTACTS:  +39 02 2390 1

A Single-arm, open-label phase 4 study of Nirogacestat in adult premenopausal females with desmoid tumors/aggressive fibromatosis (AF)

Phase: Phase IV clinical trials

Principal Investigator: Dott.ssa Stacchiotti Silvia

Main Facility: Oncologia Medica 2

Drug: Nirogacestat

Pathologies: Other

ClinicalTrials.gov: Read more about clinical trials

This clinical study is a Phase 4 study aimed at evaluating nirogacestat in adult premenopausal women affected by desmoid fibromatosis (AF). The primary objective of the study is to characterize the toxicity of nirogacestat on ovarian function, in terms of the incidence of ovarian toxicity (OT) events and the rate of recovery of ovarian function in patients treated with nirogacestat. Efficacy, safety and tolerability of the treatment will also be evaluated. 

DA is a rare form of soft tissue tumor, characterized by locally aggressive growth. Nirogacestat is a gamma-secretase inhibitory drug that acts on a mechanism involved in the growth of tumor cells, with the aim of slowing or controlling their development. 

The study is intended for women of childbearing potential, aged between 18 and 40 years, in premenopause and with a regular menstrual cycle, affected by symptomatic or progressive disease requiring systemic treatment. 

The study is also open to Patients who have received previous chemotherapy or radiotherapy treatments, provided they are still in premenopause at the time of study entry. Women who have received therapies known to be responsible for damage and permanent impairment of ovarian function, such as certain gonadotoxic chemotherapies or pelvic radiotherapy, are not eligible. 

The treatment involves oral administration of nirogacestat twice daily, in 28-day cycles, up to a maximum of 24 cycles.

Last update: 21/04/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe